CYC vs NEU

ASX Healthcare sector comparison — updated 25 Mar 2026 — Healthcare sector

CYC

CYCLOPHARM FPO [CYC]

44LOW

NEU

NEUREN FPO NZ [NEU]

44LOW

Score Breakdown

CYC NEU
Technical
65
77
Catalyst
55
50
Sentiment
50
50
Fundamental
55
60
Momentum
39
22
Risk Gate
50
43

Key Metrics

CYC Metric NEU
$91.8MMarket Cap$1.5B
98KAvg Volume (20d)705K
+0.0%Short Interest+4.4%
$1.47552-Week High$22.985
$0.56052-Week Low$8.610
+6.7%Daily Change+5.1%
$0.800Entry Price$11.880
-49.3%ROE+8.7%
-53.3%Profit Margin+47.1%

Active Signals

CYC Signals

●MACD momentum is picking up steam
●Above-average volume (1.7x) on a green day — buyers stepping up
●On a tear — up 11.1% over the last 5 days
●Below the 200-day average — the long-term trend is still working against it
●Critical cash runway (1.5 quarters)
●Low P/S ratio (2.8x)
●Moderate revenue growth (+18%)
●EPS estimates revised upward (+10pts)

NEU Signals

●RSI drifting toward oversold territory — worth watching
●MACD momentum is picking up steam
●Stochastic just turned bullish from a low level — early reversal sign
●Above-average volume (1.8x) on a green day — buyers stepping up
●Volatility is contracting — like a spring being compressed, breakouts often follow
●Below the 200-day average — the long-term trend is still working against it
●Cash positive / operating cashflow positive
●Revenue in sharp decline (-81%)

Ask Scout AI to compare CYC and NEU in depth.

Open Scout AI →

Track both stocks and 2,200+ more — Free

Daily AI-powered screening across every ASX small cap.

Open Screener
CYC Full Analysis → NEU Full Analysis → Healthcare Sector →
GENERAL INFORMATION ONLY. SmallCapData provides algorithmic screening data and does not constitute personal financial advice, a recommendation, or an offer to buy or sell any security. This content is produced by an algorithm, not a licensed financial adviser. You should consider seeking independent financial advice before making any investment decision. Past performance is not indicative of future results. Trading in small-cap securities carries a high degree of risk, including the risk of total loss of capital. The author may hold positions in mentioned securities. SmallCapData does not hold an Australian Financial Services Licence (AFSL).